DANAHER CORP /DE/

DHR 10-K · FY 2025
API behind this page

DHR FY 2025 request

Playground key active
Request URL /api/financials?ticker=DHR&year=2025&quarter=4&full_year_mode=true
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric FY 2025 FY 2024 YoY
Revenue 24,568 23,875 +2.9%
Show Product Lines breakouts
Nonrecurring 4,441 4,509 -1.5%
Nonrecurring · Biotechnology 869 1,001 -13.2%
Nonrecurring · Diagnostics 1,082 1,068 +1.3%
Nonrecurring · Life Sciences 2,490 2,440 +2.0%
Recurring 20,127 19,366 +3.9%
Recurring · Biotechnology 6,424 5,758 +11.6%
Recurring · Diagnostics 8,859 8,719 +1.6%
Recurring · Life Sciences 4,844 4,889 -0.9%
Show Business Segments breakouts
Biotechnology · High-growth markets 1,976 1,891 +4.5%
Biotechnology · North America 2,418 2,237 +8.1%
Biotechnology · Operating Segments 7,293 6,759 +7.9%
Biotechnology · Other developed markets 341 335 +1.8%
Biotechnology · Western Europe 2,558 2,296 +11.4%
Diagnostics · High-growth markets 2,922 2,933 -0.4%
Diagnostics · North America 4,920 4,859 +1.3%
Diagnostics · Operating Segments 9,941 9,787 +1.6%
Diagnostics · Other developed markets 393 408 -3.7%
Diagnostics · Western Europe 1,706 1,587 +7.5%
Life Sciences · High-growth markets 2,124 2,046 +3.8%
Life Sciences · North America 3,018 3,199 -5.7%
Life Sciences · Operating Segments 7,334 7,329 +0.1%
Life Sciences · Other developed markets 518 510 +1.6%
Life Sciences · Western Europe 1,674 1,574 +6.4%
Show Geography breakouts
All other (each country individually less than 5% of total) · Reportable Geographical Components 11,956 11,143 +7.3%
CN · Reportable Geographical Components 2,631 2,805 -6.2%
High-growth markets 7,022 6,870 +2.2%
North America 10,356 10,295 +0.6%
Other developed markets 1,252 1,253 -0.1%
US · Reportable Geographical Components 9,981 9,927 +0.5%
Western Europe 5,938 5,457 +8.8%
Show Consolidation Items breakouts
Operating Segments 24,568 23,875 +2.9%
Cost of Revenue -10,045 -9,669 -3.9%
Gross Profit 14,523 14,206 +2.2%
Selling, General & Administrative -8,235 -7,759 -6.1%
Research & Development -1,598 -1,584 -0.9%
Operating Income 4,690 4,863 -3.6%
Show Business Segments breakouts
Biotechnology · Operating Segments 1,864 1,685 +10.6%
Diagnostics · Operating Segments 2,650 2,625 +1.0%
Life Sciences · Operating Segments 520 879 -40.8%
Show Consolidation Items breakouts
Corporate Non Segment -344 -326 -5.5%
Operating Segments 5,034 5,189 -3.0%
Other Non-Operating Income (Expense) -222 -56 -296.4%
Interest Expense -265 -278 +4.7%
Interest Income 30 117 -74.4%
Income Before Taxes 4,233 4,646 -8.9%
Show Geography breakouts
Non Us 3,262 3,644 -10.5%
US 971 1,002 -3.1%
Income Tax Expense (Benefit) -633 -747 +15.3%
Income Loss From Continuing Operations 3,600 3,899 -7.7%
Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity 14 — —
Net Income 3,614 3,899 -7.3%
Show Equity Components breakouts
Retained Earnings 3,614 3,899 -7.3%
Net Income Loss Available To Common Stockholders Basic 3,614 3,899 -7.3%
Income Loss From Continuing Operations Per Basic Share 5.05 5.33 -5.3%
Income Loss From Continuing Operations Per Diluted Share 5.03 5.29 -4.9%
Income Loss From Discontinued Operations Net Of Tax Per Basic Share 0.02 — —
Income Loss From Discontinued Operations Net Of Tax Per Diluted Share 0.02 — —
EPS (Basic) 5.07 5.33 -4.9%
EPS (Diluted) 5.05 5.29 -4.5%
Wtd Avg Shares (Basic) 712.7 731 -2.5%
Wtd Avg Shares (Diluted) 716.1 737.2 -2.9%
Comprehensive Income 6,625 2,429 +172.7%
Gain Loss On Investments -248 -57 -335.1%

Balance Sheet

Balance Sheet
Metric FY 2025 FY 2024 YoY
Current Assets
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 4,615 2,078 +122.1%
Accounts Receivable 3,913 3,537 +10.6%
Inventory 2,489 2,330 +6.8%
Prepaid Expenses & Other Current Assets 1,739 1,552 +12.0%
Total Current Assets 12,756 9,497 +34.3%
Non-Current Assets
Property, Plant & Equipment 5,531 4,990 +10.8%
Show Geography breakouts
All other (each country individually less than 5% of total) · Reportable Geographical Components 1,424 1,251 +13.8%
DE · Reportable Geographical Components 287 251 +14.3%
GB · Reportable Geographical Components 586 519 +12.9%
SE · Reportable Geographical Components 477 384 +24.2%
US · Reportable Geographical Components 2,757 2,585 +6.7%
Other Non-Current Assets 4,209 3,990 +5.5%
Goodwill 43,151 40,497 +6.6%
Show Business Segments breakouts
Biotechnology · Operating Segments 23,313 21,437 +8.8%
Diagnostics · Operating Segments 6,982 6,755 +3.4%
Life Sciences · Operating Segments 12,856 12,305 +4.5%
Show Range breakouts
Maximum 23.1 — —
Minimum 1.2 — —
Total Assets 83,464 77,542 +7.6%
Show Business Segments breakouts
Biotechnology · Operating Segments 37,337 34,605 +7.9%
Diagnostics · Operating Segments 14,748 14,204 +3.8%
Life Sciences · Operating Segments 23,112 23,211 -0.4%
Show Consolidation Items breakouts
Corporate Non Segment 8,267 5,522 +49.7%
Operating Lease Right-of-Use Assets 1,214 1,084 +12.0%
Other Assets
Intangible Assets Net Excluding Goodwill 17,817 18,568 -4.0%
Current Liabilities
Debt Current 2 505 -99.6%
Accounts Payable Trade Current 1,844 1,753 +5.2%
Accrued Liabilities 4,961 4,540 +9.3%
Total Current Liabilities 6,807 6,798 +0.1%
Deferred Revenue (Current) 1,353 1,299 +4.2%
Non-Current Liabilities
Other Non-Current Liabilities 5,700 5,694 +0.1%
Long-Term Debt 18,416 15,500 +18.8%
Long-Term Debt 18,418 16,005 +15.1%
Show Debt Instrument breakouts
0.2% senior unsecured notes due 2026 · Senior Notes 1,469 1,293 +13.6%
0.3% senior unsecured notes due 2027 · Senior Notes 196 195 +0.5%
0.45% senior unsecured notes due 2028 · Senior Notes 1,466 1,291 +13.6%
0.4773% 2027 CHF Bonds · Bonds 315 — —
0.65% senior unsecured notes due 2032 · Senior Notes 339 337 +0.6%
0.75% senior unsecured notes due 2031 · Senior Notes 2,050 1,805 +13.6%
0.88755 2029 CHF Bonds · Bonds 409 — —
1.125% senior unsecured bonds due 2028 · Bonds 267 233 +14.6%
1.2% senior unsecured notes due 2027 · Senior Notes 704 620 +13.5%
1.265% 2033 CHF Bonds · Bonds 408 — —
1.35% senior unsecured notes due 2039 · Senior Notes 1,456 1,282 +13.6%
1.6249% 2037 CHF Bonds · Bonds 282 — —
1.8% senior unsecured notes due 2049 · Senior Notes 873 769 +13.5%
1.94% 2045 CHF Bonds · Bonds 157 — —
2.1% senior notes due 2026 · Senior Notes 940 828 +13.5%
2.5% senior notes due 2030 · Senior Notes 940 829 +13.4%
2.6% senior unsecured notes due 2029 · Senior Notes 798 797 +0.1%
2.6% senior unsecured notes due 2050 · Senior Notes 983 982 +0.1%
2.8% senior unsecured notes due 2051 · Senior Notes 985 985 0.0%
3.25% senior unsecured notes due 2039 · Senior Notes 892 892 0.0%
3.4% senior unsecured notes due 2049 · Senior Notes 891 890 +0.1%
4.375% senior unsecured notes due 2045 · Senior Notes 500 499 +0.2%
Euro-denominated commercial paper · Commercial Paper 933 931 +0.2%
Euro-Denominated Commercial Paper, 2026 Biopharma Euro Notes and 2026 Euro Notes 3.5 — —
Other 1 13 -92.3%
Operating Lease Liabilities 1,079 968 +11.5%
Accrued Income Taxes Noncurrent 3,013 3,138 -4.0%
Contract With Customer Liability Noncurrent 231 232 -0.4%
Stockholders' Equity
Common Stock 9 9 0.0%
Additional Paid In Capital Common Stock 17,194 16,727 +2.8%
Treasury Stock Common Value -11,353 -8,163 -39.1%
Retained Earnings 46,891 44,188 +6.1%
Accumulated Other Comprehensive Income -207 -3,218 +93.6%
Total Stockholders' Equity 52,534 49,543 +6.0%
Minority Interest 7 7 0.0%
Stockholders Equity Including Portion Attributable To Noncontrolling Interest 52,541 49,550 +6.0%
Show Equity Components breakouts
Accumulated Defined Benefit Plans Adjustment -185 -300 +38.3%
Accumulated Gain Loss Net Cash Flow Hedge Parent 217 -14 +1650.0%
Accumulated Other Comprehensive Income -207 -3,218 +93.6%
Accumulated Translation Adjustment -239 -2,904 +91.8%
Additional Paid In Capital 17,194 16,727 +2.8%
Common Stock 9 9 0.0%
Noncontrolling Interest 7 7 0.0%
Retained Earnings 46,891 44,188 +6.1%
Treasury Stock Common -11,353 -8,163 -39.1%
Total Liabilities & Equity 83,464 77,542 +7.6%

Cash Flow Statement

Cash Flow Statement
Metric FY 2025 FY 2024 YoY
Operating Activities
Depreciation 750 721 +4.0%
Show Business Segments breakouts
Biotechnology · Operating Segments 149 151 -1.3%
Diagnostics · Operating Segments 407 394 +3.3%
Life Sciences · Operating Segments 185 167 +10.8%
Show Consolidation Items breakouts
Corporate Non Segment 9 9 0.0%
Operating Segments 741 712 +4.1%
Amortization Of Intangible Assets 1,697 1,631 +4.0%
Show Business Segments breakouts
Biotechnology · Operating Segments 902 863 +4.5%
Diagnostics · Operating Segments 191 192 -0.5%
Life Sciences · Operating Segments 604 576 +4.9%
Show Consolidation Items breakouts
Operating Segments 1,697 1,631 +4.0%
Stock-Based Compensation 298 288 +3.5%
Asset Impairment Charges 562 265 +112.1%
Show Business Segments breakouts
Biotechnology · Operating Segments 101 — —
Diagnostics · Operating Segments 15 43 -65.1%
Life Sciences · Operating Segments 446 222 +100.9%
Life Sciences · Trade Names 432 222 +94.6%
Life Sciences, Biotechnology and Diagnostics Segment 130 — —
Show Consolidation Items breakouts
Operating Segments 562 265 +112.1%
Show Income Statement Location breakouts
Cost Of Sales 29 — —
Increase Decrease In Deferred Income Taxes -440 -483 +8.9%
Change in Accounts Receivable -216 331 -165.3%
Change in Inventory -58 147 -139.5%
Change in Accounts Payable 9 19 -52.6%
Change in Prepaid & Other Assets -55 274 -120.1%
Increase Decrease In Other Accounts Payable And Accrued Liabilities 41 -486 +108.4%
Net Cash Provided By Used In Operating Activities Continuing Operations 6,416 6,688 -4.1%
Net Cash from Operations 6,416 6,688 -4.1%
Investing Activities
Capital Expenditures -1,156 -1,392 +17.0%
Proceeds From Sale Of Property Plant And Equipment 33 13 +153.8%
Payments To Acquire Investments -127 -331 +61.6%
Proceeds From Sale Maturity And Collections Of Investments 12 253 -95.3%
Proceeds From Sale Of Product Line 9 — —
Other Investing Activities 33 34 -2.9%
Net Cash Provided By Used In Investing Activities Continuing Operations -1,196 -1,981 +39.6%
Net Cash from Investing -1,196 -1,981 +39.6%
Financing Activities
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options 85 162 -47.5%
Payments Of Dividends -878 -768 -14.3%
Proceeds From Repayments Of Short Term Debt Maturing In Three Months Or Less -11 5 -320.0%
Proceeds From Debt Maturing In More Than Three Months 1,556 — —
Repayments Of Debt Maturing In More Than Three Months -500 -1,674 +70.1%
Share Repurchases -3,088 -5,979 +48.4%
Proceeds From Payments For Other Financing Activities -125 -131 +4.6%
Net Cash Provided By Used In Financing Activities Continuing Operations -2,961 -8,385 +64.7%
Net Cash from Financing -2,961 -8,385 +64.7%
Tax Withholding for Share Compensation 69 97 -28.9%
Supplemental
Income Taxes Paid 1.2 1.3 -7.7%
Interest Paid 331 370 -10.5%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 278 -108 +357.4%
Net Change in Cash 2,537 -3,786 +167.0%
Investment Gains Losses Pretax Gain On Sale Of Product Line And Other -228 -57 -300.0%

Values in millions USD. Source: SEC EDGAR 10-K filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key